4 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow AT7519M: new trials by email Literature Review of AT7519M trials Research Report on AT7519M
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery CDK Inhibitor AT7519, Laboratory Biomarker Analysis, Onalespib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2016-09-30 | 2025-02-10 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma AT7519M - Mantle Cell Lymphoma | Phase 2 | Completed | NCIC Clinical Trials Group | 12 | 2012-09-14 | 2023-08-04 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia AT7519M - Chronic Lymphocytic Leukemia | Phase 2 | Completed | NCIC Clinical Trials Group | 7 | 2012-08-27 | 2023-08-04 |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma AT7519M, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 18 | 2010-11-01 | 2024-08-02 |
Blood Protein Disorders (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1)
NCIC Clinical Trials Group (2) · Astex Pharmaceuticals, Inc. (1) · National Cancer Institute (NCI) (1)
Canada (2) · United States (2)
John Kuruvilla (1) · Khanh T Do (1) · Matthew D Seftel (1)
UM1CA186709 (1), ZIABC011078 (1)